Industry News
Biotechnology Industry News
GSK’s cobolimab has become the…
GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure.
Kissei Pharmaceutical is paying…
Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye disease drug candidates, establishing the drugmaker as a potential rival to Amgen.
As Merck & Co. rolls out a…
As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.
Fortrea and Flourish Research…
Fortrea and Flourish Research leaders discuss how strategic collaboration are improving outcomes in large-scale cardiovascular trials.
Quoin Pharmaceuticals has ended…
Quoin Pharmaceuticals has ended development of two programs, pulling back from the assets as it starts to gear up for the anticipated approval of its lead candidate.
Bausch Health has struck a deal to…
Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.
Bristol Myers Squibb is spinning…
Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain Capital-led financing as part of the Big Pharma’s ambitious cost-cutting drive.
AstraZeneca has dropped the lead…
AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout.
After assuring investors last week…
After assuring investors last week that beleaguered Sarepta Therapeutics would likely fulfill its financial duties in a deal with Arrowhead Pharmaceuticals, the latter has publicly stated that it has surpassed the threshold to earn its
Radiopharmaceuticals-focused…
Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through phase 2 trials and bolster its supply chain.
After months of searching for…
After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. Once the deal closes, Adaptimmune will
MapLight Therapeutics has raised a…
MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for its would-be challenger to Bristol Myers Squibb’s schizophrenia treatment Cobenfy.
Boehringer Ingelheim is continuing…
Boehringer Ingelheim is continuing to explore its newfound interest in eye health, penning a $1 billion biobucks pact with Re-Vana Therapeutics.
A phase 3 trial of Celcuity’s…
A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for success to tee up a filing for FDA approval in the fourth quarter.
Atai Life Sciences’…
Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study.
Having recently scored approval…
Having recently scored approval for Nucala in COPD, GSK has now signed a major $12 billion biobucks deal designed to strengthen the pharma’s offering for the respiratory condition.
Chinese biotech Leads Biolabs has…
Chinese biotech Leads Biolabs has hit the Hong Kong stock exchange, snagging $189 million through an initial public offering on the HKEX.
Bristol Myers Squibb has raided…
Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to leave the Anglo-Swedish drugmaker to take responsibility for all its product development.
The uncertainty around the future…
The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech.
A phase 2 trial of Memo…
A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw promise in other aspects of